论文部分内容阅读
对11例治疗相关MDS或白血病患儿进行Allo-BMT,分析移植相关毒性和预后。11例患儿(男5例,女6例),诊断原发病时中位年龄8岁(0.9～15岁),1例为ALL,其余为实体瘤。1例用烷化剂联合放疗,其余均以烷化剂和DNA拓扑异构酶抑制剂联合化疗。继发性急性白血病或MDS的发生与原发病诊断间隔的中位时间为33个月(17～112个月),11例中9例染色体异常,4例RAEB移植前未化疗,移植时外周血无原始细胞,4例接受HLA相合的同胞供者的骨髓,7例接受非亲属供者的骨髓。
Allo-BMT was performed on 11 children with MDS or leukemia and analyzed for graft-related toxicity and prognosis. Eleven patients (5 males and 6 females) had a median age of 8 years (0.9 to 15 years) at the time of diagnosis of the primary disease, 1 was ALL, and the rest were solid tumors. 1 case of alkylating agent combined with radiotherapy, the rest are alkylating agents and DNA topoisomerase inhibitors combined with chemotherapy. The median time to diagnosis of secondary acute leukemia or MDS was 33 months (range, 17 to 112 months) in the diagnosis of primary disease, 9 in 11 cases of chromosomal abnormalities, 4 cases of non-chemotherapy prior to RAEB transplantation, There were no primary blood cells in the blood, 4 received HLA-matched sibling donor bone marrow, and 7 received bone marrow from a non-relative donor.